secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001493152-22-035117
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus Board decides not to execute reverse stock split in 2022; plans to seek approval again in 2023
--------------------------------------------------------------------------------

- Board decided not to undertake the reverse stock split and authorized share reduction approved at 2022 Annual Meeting.
- Decision based on prospective factors and potential negative capital markets behavior, per Chair Ed Pershing.
- Board expects to seek same stockholder approval again in 2023 at a special or annual meeting.
- Provectus trades on OTCQB under ticker PVCT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315222035117/0001493152-22-035117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315222035117/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer